GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (NAS:TCON) » Definitions » Piotroski F-Score

TRACON Pharmaceuticals (TRACON Pharmaceuticals) Piotroski F-Score : 6 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TRACON Pharmaceuticals has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for TRACON Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

TCON' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 2   Max: 6
Current: 6

During the past 12 years, the highest Piotroski F-Score of TRACON Pharmaceuticals was 6. The lowest was 2. And the median was 2.


TRACON Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for TRACON Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TRACON Pharmaceuticals Piotroski F-Score Chart

TRACON Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 4.00 2.00 6.00

TRACON Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 3.00 4.00 6.00

Competitive Comparison of TRACON Pharmaceuticals's Piotroski F-Score

For the Biotechnology subindustry, TRACON Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TRACON Pharmaceuticals's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where TRACON Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -8.504 + -6.286 + 10.763 + 0.439 = $-3.59 Mil.
Cash Flow from Operations was -5.003 + -5.851 + 15.052 + -0.522 = $3.68 Mil.
Revenue was 0 + 9 + 0 + 3.045 = $12.05 Mil.
Gross Profit was 0 + 9 + 0 + 3.045 = $12.05 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(19.469 + 8.323 + 12.19 + 9.413 + 10.105) / 5 = $11.9 Mil.
Total Assets at the begining of this year (Dec22) was $19.47 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $9.09 Mil.
Total Current Liabilities was $10.18 Mil.
Net Income was -9.473 + -6.23 + -6.435 + -6.997 = $-29.14 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(26.557 + 18.864 + 15.677 + 19.666 + 19.469) / 5 = $20.0466 Mil.
Total Assets at the begining of last year (Dec21) was $26.56 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $18.23 Mil.
Total Current Liabilities was $22.37 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TRACON Pharmaceuticals's current Net Income (TTM) was -3.59. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TRACON Pharmaceuticals's current Cash Flow from Operations (TTM) was 3.68. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-3.588/19.469
=-0.18429298

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-29.135/26.557
=-1.09707422

TRACON Pharmaceuticals's return on assets of this year was -0.18429298. TRACON Pharmaceuticals's return on assets of last year was -1.09707422. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

TRACON Pharmaceuticals's current Net Income (TTM) was -3.59. TRACON Pharmaceuticals's current Cash Flow from Operations (TTM) was 3.68. ==> 3.68 > -3.59 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/11.9
=0

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0/20.0466
=0

TRACON Pharmaceuticals's gearing of this year was 0. TRACON Pharmaceuticals's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=9.09/10.182
=0.89275192

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=18.228/22.371
=0.81480488

TRACON Pharmaceuticals's current ratio of this year was 0.89275192. TRACON Pharmaceuticals's current ratio of last year was 0.81480488. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

TRACON Pharmaceuticals's number of shares in issue this year was 1.98. TRACON Pharmaceuticals's number of shares in issue last year was 1.115. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=12.045/12.045
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

TRACON Pharmaceuticals's gross margin of this year was 1. TRACON Pharmaceuticals's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=12.045/19.469
=0.61867584

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/26.557
=0

TRACON Pharmaceuticals's asset turnover of this year was 0.61867584. TRACON Pharmaceuticals's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TRACON Pharmaceuticals has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

TRACON Pharmaceuticals  (NAS:TCON) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


TRACON Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


TRACON Pharmaceuticals (TRACON Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.
Executives
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer director, officer: President and CEO C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams officer: Chief Operating Officer C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown officer: Chief Accounting Officer (PAO) C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue director C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins officer: Chief Business Officer 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani 10 percent owner, other: Member of 10% Group 12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc 10 percent owner 950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022

TRACON Pharmaceuticals (TRACON Pharmaceuticals) Headlines

From GuruFocus

Could Insider Buying Signal that TRACON Pharmaceuticals Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 09-26-2022